SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel Corp is trending following news of a $5 billion investment from Nvidia, sparking discussions about a potential deeper partnership in AI and chip manufacturing. The community is analyzing the implications for Intel's foundry business and competitive positioning against AMD, with some speculating about future collaborations with other major tech players. This move is viewed as a strategic effort to strengthen US-based chip production and innovation amid global competition.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as community members express enthusiasm for the "culture coin" and its potential. Discussions highlight the strength and positivity of the Weedcoin community, emphasizing the cultural movement it represents. Some community members are expressing long term bullish sentiment for Weedcoin.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSpark (CLSK) is trending amid discussions of a potential pivot towards AI and high-performance computing, sparked by recent CEO commentary. The community is actively watching key resistance levels, with some anticipating a catch-up rally relative to sector peers, while highlighting the stock's heavily shorted position.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

Brera Holdings (BREA) is trending as it rebrands to Solmate, focusing on Solana's digital asset treasury, infrastructure, and UAE validator expansion, which has drawn backing from ARK Invest and a $300M private investment. Community discussions revolve around the potential for significant gains and comparisons to other crypto treasury plays, though some express concerns about valuation and potential dilution. Overall, the conversation centers on whether BREA can sustain its momentum and capitalize on the Solana ecosystem.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending due to Baird's analyst upgrading the stock to Outperform and significantly raising the price target, sparking debate among investors about its valuation. Community discussions also revolve around the potential impact of a US-India tariff truce on Tesla's market and the departure of a key member from the Optimus AI team.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

Disney is trending due to mixed reactions surrounding the launch of ESPN's new streaming service and the abrupt cancellation of Jimmy Kimmel's show, sparking debates about free speech and potential boycotts. The community is actively discussing subscription cancellations and the implications for Disney's brand, with some seeing a political dimension affecting the company's appeal to both conservative and liberal audiences. Broader discussions involve Disney's strategic shifts in streaming and the potential impact on its financial performance amid broader media landscape changes.

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment consists of end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through the company's two core offerings, Canopy and Horizon. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

DNA is trending due to community discussion around its partnerships, particularly with Bayer, for nitrogen fixation in corn and other crops, potentially reducing the need for fertilizers. Some investors are also discussing the potential for biomanufacturing to return to the US, driven by deals involving corn and biodegradable products. Additionally, a recent settlement with investors related to a previous report is circulating, informing investors on how to file a claim.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

EBS is trending as investors discuss potential European contracts amidst increased defense spending and the company's search for a European government affairs director. The community is also analyzing recent options activity and contract awards, with some expressing frustration over short selling and a desire for management to address the low share price. Discussions also include Ebola outbreaks, rate cut impacts, and speculation around future revenue and debt refinancing.

Literally a dog wif a hat, dogwifhat (WIF) is a meme coin that's part of the ever-growing ecosystem of digital currencies on the Solana blockchain. This token brings a lighthearted twist to cryptocurrency, featuring a playful dog with a hat as its mascot, symbolising a more whimsical approach to the often serious domain of digital finance.

dogwifhat

Dogwifhat ($WIF.X) is trending as the crypto attempts to break through the $1 resistance level, sparking discussions about its volatile price action and potential for significant gains. Community members are actively debating whether it will follow the path of other meme coins like $DOGE.X and $SHIB.X, while some express frustration with its inability to sustain upward momentum.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending amidst a notable price decline, sparking discussions about potential causes, including competition from Meta and the impact of AI on digital advertising. The community is actively debating whether this represents a buying opportunity or a value trap, with some expressing frustration over the stock's performance despite positive fundamentals, and others pointing to the upcoming Google ad tech trial as a potential catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

U.S. equities declined in Tuesday’s midday trade, with the crucial two-day Federal Open Market Committee (FOMC) meeting currently underway.Ahead of the release of the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fed-meeting-date-fomc-rate-decision-when-announce-what-to-expect/chwynHURdzn">Fed meeting's outcome</a>, President Donald Trump&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-fed-should-be-independent-should-listen-to-smart-people-like-me/chwylmVRdzX">called on</a> the central bank to listen to “smart people” like himself, while stating that the central bank should remain independent.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.16% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq, fell 0.11%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, declined 0.26%.Here are the top stocks making the biggest moves in Tuesday’s midday trade:<a href="https://stocktwits.com/symbol/BBAI">BigBear.ai Holdings Inc. (BBAI)</a>BigBear.ai shares were up more than 15% in Tuesday’s midday trade after a recent&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bigbear-sparks-retail-buzz-as-congressional-disclosure-fuels-federal-win-rumor/chwy743RdyX">disclosure</a> by Representative Lisa McClain (R-Mich.) regarding the purchase of BBAI stock worth between $15,000 and $50,000 as part of a 401K account held with Charles Schwab. BigBear.ai was the top trending stock on Stocktwits at the time of writing.<a href="https://stocktwits.com/symbol/BBAI">BBAI stock</a> is up 32% year-to-date.<a href="https://stocktwits.com/symbol/TSLA">Tesla Inc. (TSLA)</a>Tesla shares continued to rise, gaining nearly 3% in Tuesday’s midday session following a surge on Monday after co-founder and CEO Elon Musk&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-shares-surge-elon-musk-purchases-stock-first-time-since-2020/chwwIvpRdUG">acquired</a> 2.57 million shares of the company on Friday, at an aggregate value of nearly $1 billion.<a href="https://stocktwits.com/symbol/TSLA">TSLA stock</a> is up 4% year-to-date.<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers Health Inc. (HIMS)</a>Hims &amp; Hers Health shares dropped by over 7% in Tuesday’s midday trade after the U.S. Food and Drug Administration (FDA)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-stock-tumbles-7-percent-after-fda-letter/chwyNFWRdzV">sent</a> a letter alleging that the company’s claims concerning compounded Semaglutide products, used for weight loss, are “false or misleading.”<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is up 109% year-to-date.<a href="https://stocktwits.com/symbol/RKLB">Rocket Lab Corp. (RKLB)</a>Rocket Lab shares dropped over 12% in Tuesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rocket-lab-stock-tumbles-10-percent-today-here-is-what-happened/chwyZ66Rdzl">announced</a> a $750 million at-the-market (ATM) equity offering.<a href="https://stocktwits.com/symbol/RKLB">RKLB stock</a> is up 87% year-to-date.<a href="https://stocktwits.com/symbol/WBD">Warner Bros. Discovery Inc. (WBD)</a>Warner Bros. Discovery shares fell over 8% in Tuesday’s midday trade after analysts at TD Cowen downgraded the stock to ‘Hold’ from ‘Buy’ on concerns that “there would be a lot of hurdles” in Paramount Skydance Corp.’s (PSKY)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-reportedly-plans-majority-cash-bid-for-warner-bros-discovery/chwNp8zRdvx">reported</a> bid to acquire the former, according to TheFly. Senator Elizabeth Warren on Tuesday also voiced her disapproval, calling to block the deal, and said in a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/ewarren/status/1967936711264272677">post</a> on X that it “would be a dangerous concentration of power over our media and news.”<a href="https://stocktwits.com/symbol/WBD">WBD stock</a> is up 69% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fed-meeting-date-fomc-rate-decision-when-announce-what-to-expect/chwynHURdzn">Fed Meeting Date: Here's When FOMC's Rate Decision Will Be Announced, And What You Should Expect</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

BigBear.ai, Tesla, Hims & Hers, Rocket Lab, Warner Bros Discovery: Stocks Making The Biggest Moves Today

BigBear.ai shares were up more than 15% on Tuesday after a recent disclosure by Representative Lisa McClain regarding the purchase of BBAI stock worth between $15,000 and $50,000.

Equity

Shares of Hims &amp; Hers Health (HIMS) slumped 7% on Tuesday after the U.S. Food and Drug Administration (FDA) sent a letter to the company CEO regarding the sale of compounded drug products.In the letter <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hers-09092025">dated</a> September 9, the agency alleged that the company’s claims concerning compounded Semaglutide products, used for weight loss, are “false or misleading.” The FDA also noted that this is a violation of certain sections of the Federal Food, Drug, and Cosmetic Act.The FDA pointed out that compounded drug products are not approved by it. “Your claims imply that your products are the same as an FDA-approved product when they are not,” the letter said, while urging the company to take immediate action to address violations. A failure to adequately address any violation may result in legal action without further notice, it added.The FDA further alleged that these compounded products are misbranded and noted that the introduction of misbranded products into interstate commerce is prohibited. While the letter referred to two claims made on compounded Semaglutide products made on Hims’ website, it does not represent an exhaustive list of misbranding violations, the agency said.The FDA has given CEO Andrew Dudum 15 working days from the receipt of the letter to provide a written response describing the steps taken to address violations or to provide reasoning and supporting information if he believes the company is not in violation.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> jumped from ‘bullish’ to 'extremely bullish' territory over the past 24 hours, while message volume stayed at ‘high’ levels.In June, Novo Nordisk (NVO) <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-plunges-after-novo-nordisk-ends-wegovy-partnership/chm55y3RR5v">said</a> that it is halting collaboration with Hims &amp; Hers for the sale of its blockbuster weight loss drug Wegovy, the key ingredient of which is Semaglutide. Novo said that Hims &amp; Hers failed to adhere to the law, which prohibits mass sales of compounded drugs. It further alleged that the telehealth operator is promoting and selling illegitimate, knockoff versions of Wegovy and has hence decided to halt the collaboration entered into in late April.Dudum, however, subsequently <a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-hits-back-at-novo-nordisk-after-collaboration-end/chm5fs2RRd4">alleged</a> that Novo’s management is “misleading the public.” The CEO stated in a post on X that the pharmaceutical company’s commercial team has been pressuring the company to control clinical standards and steer patients toward Wegovy, regardless of whether it is clinically the best option for patients.HIMS stock has more than doubled its value this year and tripled over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-to-set-up-5-billion-facility-in-virginia/chwymFcRdzj">Eli Lilly To Set Up $5B Facility In Virginia – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen on May 04, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Hims & Hers Stock Draws Investor Attention After Tumbling 7% – Here’s What Happened

In a letter dated September 9, the FDA alleged that the company’s claims concerning compounded Semaglutide products are “false or misleading.”

Hims & Hers Expands AI and Technology Focus to Advance Digital Care

HIMS boosts AI investment and appoints a new CTO as it advances personalized, technology-driven digital healthcare at scale.

Company News for Sep 16, 2025

Companies in The News Are: NVDA,HIMS,MSFT,NFLX

Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: Here's Why

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $54.03, signifying a -2.65% move from its prior day's close.

OMCL or HIMS: Which Is the Better Value Stock Right Now?

OMCL vs. HIMS: Which Stock Is the Better Value Option?

Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Hims & Hers Surges 64.1% in 6 Months: How to Play the Stock?

HIMS accelerates with new men's health launches, global expansion plans and strong subscriber-driven growth, but rising costs strain gross margins.

The last few months have seen a resurgence in social media-driven stock trades,&nbsp;resulting in a crop of new meme stocks,&nbsp;including Opendoor, GoPro, Kohl's, and Krispy Kreme.Now, JPMorgan has identified a few more names to keep a tab on. "We are flagging a few stocks that are heavily mentioned on Social Media and have high Retail buying as well as high Hedge fund Shorting," the investment research said in a note to clients, according to<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/09/11/four-meme-stocks-with-high-social-activity-and-hedge-funds-shorts-according-to-jpmorgan.html">&nbsp;CNBC</a>. "These stocks may experience unexpected flows in case of increased activity."Here are JPMorgan's picks and brief notes on their recent moves:&nbsp;Hims &amp; Hers HealthThe weight loss and health management company's stock has fluctuated significantly between peaks and troughs. Earlier this year, the company entered into a partnership with Novo Nordisk to distribute the latter's Wegovy, a popular GLP-1 weight loss drug. However, a few months later, the Danish pharmaceutical major canceled the partnership, citing Hims &amp; Hers' failure to prevent "knockoff" compounded versions of Wegovy and for engaging in deceptive marketing.U.S. regulators have rapped Hims &amp; Hers for its drug marketing practices, and investors are closely watching the company's moves.Year-to-date gain: 110%Short interest: 31.1%Stocktwits sentiment:&nbsp;Bullish&nbsp;ImmunityBioThe cancer-focused biotech firm has seen interest, driven by clinical-stage Anktiva,&nbsp;designed to boost the immune system's tumor-fighting response, and&nbsp;immunotherapies that target and kill cancer cells. Although the company's stock has mostly&nbsp;traded rangebound this year, shares have jumped double-digit percentages on several occasions in reaction to positive trial data.Year-to-date gain: 0.4%Short interest: 8%Stocktwits sentiment:&nbsp;Bullish&nbsp;Rocket CompaniesThe mortgage and house-owning services firm has seen its stock climb steadily this year, with a recent bump accompanying renewed expectations of a potential lowering of interest rates. The stock hit a 52-week high earlier this week.In March, the Rocket Companies announced a massive $9.4-billion all-stock acquisition of competitor Mr. Cooper Group, lifting investor confidence. The company's business is closely tied to the housing market, which is experiencing a modest rebound.Year-to-date gain: 97%Short interest: 5.3%Stocktwits sentiment:&nbsp;Bullish&nbsp;SoundHound AIAfter a whopping 836% rise in 2024, SoundHound shares have traded comparatively sombrely this year. That said, several analysts have recently begun covering the company, impressed by its voice-based AI technology.In July, the company reported a 217% rise in its second-quarter revenue and increased its sales guidance for the whole year.Year-to-date loss: 29%Short interest: 28.7%Stocktwits sentiment:&nbsp;Bullish&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/rent-the-runway-stocks-plummets-27-after-hours-on-mounting-losses-surging-costs-retail-traders-still-bullish/chw8hPeRdwL">&nbsp;Rent The Runway Stocks Plummets 27% After-Hours On Mounting Losses, Surging Costs — Retail Traders Still Bullish</a>

Traders work on the floor of the New York Stock Exchange during morning trading on August 26, 2025, in New York City. 

Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts

Meme mania has resurged in the past few months.

Shares of Hims &amp; Hers Health, Inc. (HIMS) rose 3% on Wednesday after the telehealth company launched a new category in men’s health, offering access to innovative, affordable, and personalized treatment plans for low testosterone.The company estimates that over 20 million men in the U.S. struggle with low testosterone, but noted that most never receive care due to stigma, outdated treatments, and high costs.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> stayed within the ‘bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels. According to Stocktwits data, retail chatter around the stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday.<figure class="image"><img style="aspect-ratio:624/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_10_at_12_36_35_PM_png_dcb797f889.webp" alt="HIMS's Sentiment Meter and Message Volume as of 12:36 p.m. ET on Sept. 10, 2025 | Source: Stocktwits" width="624" height="61"><figcaption>HIMS' Sentiment Meter and Message Volume as of 12:36 p.m. ET on Sept. 10, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that the stock continues to rally without offering a favorable entry point.<stembedurl>https://stocktwits.com/Canyonfundstrader2007/message/628171596</stembedurl>Hims <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.hims.com/news/news-details/2025/Hims-Launches-New-Category-in-Mens-Health-with-Exclusive-Branded-Oral-Testosterone-and-Expanded-Personalized-Treatments/default.aspx">said</a> on Wednesday that low testosterone, if left untreated, can drain energy, dull mood and sexual desire, and raise risks of heart disease, diabetes, and cancer. Starting in 2026, the company will launch a branded oral testosterone called Kyzatrex through a collaboration with Marius Pharmaceuticals. Kyzatrex is FDA-approved and has been shown to restore testosterone levels in up to 96% of men, Hims said.The company also stated that it will introduce access to injectable testosterone treatments in 2026. Providers will also be able to prescribe tailored doses of compounded Enclomiphene for men experiencing sexual symptoms through the Hims &amp; Hers platform starting Wednesday, the company said. Enclomiphene has been shown to double testosterone levels by restoring natural testosterone production, the company stated. Bloomberg <a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-to-launch-low-testosterone-treatments-for-men-as-weight-loss-drug-sales-slow/chwjw9LRdt6">reported</a> that Hims will make the announcement earlier in the day.&nbsp;Separately, on Tuesday, the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) announced a major reform of pharmaceutical advertisements, which will require drug companies to include full safety warnings in their direct-to-consumer ads.According to BofA analyst Allen Lutz, these industry changes are likely to make new customer conversions more challenging through ads, given the competitive pressures in the sexual health, hair loss, and weight loss sectors. Overall, Hims &amp; Hers should be able to navigate this environment given its strong brand equity and first-mover advantage, the analyst said, while adding that it would expect continued volatility in the near term.The firm kept an ‘Underperform’ rating on Hims &amp; Hers with a price target of $28 on the shares.HIMS stock has more than doubled in value this year and more than tripled over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/merck-reportedly-scraps-research-centre-in-uk/chwkKULRdut">Merck Reportedly Scraps Research Centre In UK: Retail Sees Stock Rallying To $97.50</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hims & Hers Stock Rises After Company Launches Treatment Plans For Low Testosterone

According to Stocktwits data, retail chatter around HIMS stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$55.68
Prev Close	$50.35
Open	$50.40
Dividend Yield	0.00%
50-Day Moving Average	$50.67
Beta	1.87
Avg. Volume	29.3M
PE Ratio	70.34

52-Week High	$72.98
52-Week Low	$15.73
Market Capitalization	$12.7B
EPS (Annual)	$0.5322
Price to Book	22.55
Revenue Per Employee	$901,963.35
Enterprise Value/EBITDA	N/A

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HIMS News

HIMS Hims & Hers Health Inc